- ECONOMIC IMPACT -

Latest update: 20 January 

According to the Organisation for Economic Co-operation and Development (OECD), unemployment rates in OECD nations declined marginally to 6.9% in November 2020 from 7.1% in October 2020.

The Chinese economy expanded by 6.5% (YoY) in Q4 2020, taking the full year growth to 2.3% in 2020, the slowest rate in more than four decades, according to National Bureau of Statistics.

4%

World Bank forecasts global economic growth at 4% in 2021 as vaccine rollout becomes widespread.

-3.7%

Consensus forecast for world GDP growth in 2020 is now -3.7%.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 02 February 

Vaccine development

$100bn

Prophylactic vaccines are predicted to generate total sales of over $100bn from 2020 to 2026.

 2026

Peak sales for many Covid-19 therapeutic drugs is forecast to occur in 2026, which could be due to several of these drugs receiving approvals for other indications.

Pharmaceutical Value Chain impact

The Covid-19 pandemic has created a massive global effort centered around finding effective therapeutics and vaccines.


While development and commercialisation of a safe vaccine typically takes at least several years to materialise, Pfizer/BioNTech Covid-19 has beaten that timeline by a considerable margin with the UK becoming the first market to approve the jab.


Nevertheless, with pharmaceutical companies shifting their strategies to focus on the development of Covid-19-related assets, the non-Covid-19 drug development programs have been brought to a temporary backseat.


Developers with Covid-19 therapies and vaccines will benefit in the short-term, as intense investor interest will drive up stock prices and provide these companies with cash and resources to further pipeline development. 

Key pharma market developments

Share this article

Go to article: Home | Getting the skinny on generics labellingGo to article: In this issueGo to article: ContentsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: The Solubility companyGo to article: The Solubility Company Insight Go to article: CommentGo to article: Market access of orphan designated therapies at riskGo to article: Lodo Therapeutics’ AI-driven natural drug discovery platformGo to article: Concert Pharmaceuticals discontinues schizophrenia drug after trial failureGo to article: Medical cannabis in Europe: a compelling opportunityGo to article: Exploring the pharma deals outlook in 2021Go to article: In DepthGo to article: Skinny labelling of generics: the beginning of the end for this practice?Go to article: Charting the choppy history of ‘magic bullet’ antibody-drug conjugates Go to article: How a sleeping drug awakened a patient with akinetic mutismGo to article: Breast cancer research: addressing the pre-menopausal problemGo to article: Beyond the lung: treating the GI symptoms of Covid-19Go to article: Immortal cells and informed consent: the legacy of Henrietta LacksGo to article: How radiopharmaceuticals are helping fight cancer with Fusion Go to article: Competition heats up as new HIV prevention drug shows promise Go to article: BaxterGo to article: ACG WorldwideGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue